Non-small cell to small cell lung cancer on PD-1 inhibitors: two cases on potential histologic transformation

Autor: Abdallah N, Nagasaka M, Abdulfatah E, Shi D, Wozniak AJ, Sukari A

Publikováno v: Lung Cancer: Targets and Therapy, Vol Volume 9, Pp 85-90 (2018)

Nadine Abdallah,1 Misako Nagasaka,2,3 Eman Abdulfatah,4 Dongping Shi,4 Antoinette J Wozniak,2 Ammar Sukari2 1Department of Internal Medicine, Wayne State University, Detroit, MI 48201, USA; 2Department of Oncology, Barbara Ann Karmanos Cancer Institu

Externí odkaz: https://doaj.org/article/5ec7a9bbf8d14c17a509a9cc8032296a

Short Report of a Phase II Trial of Nintedanib in Recurrent Malignant Pleural Mesothelioma (MPM).

Autor: Wozniak AJ; Division of Hematology/Oncology, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA. Electronic address: wozniakaj@upmc.edu., Schneider B; Department of Medicine, University of Michigan, Ann Arbor, MI., Kalemkerian GP; Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI., Daly B; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Chen W; Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI., Ventimiglia J; Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI., Nagasaka M; Division of Hematology/Oncology, Department of Medicine, University of California, Orange, CA., Zauderer MG; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.

Publikováno v: Clinical lung cancer [Clin Lung Cancer] 2023 Sep; Vol. 24 (6), pp. 563-567. Date of Electronic Publication: 2023 Apr 07.

Brief Report: Safety and Antitumor Activity of Durvalumab Plus Tremelimumab in Programmed Cell Death-(Ligand)1-Monotherapy Pretreated, Advanced NSCLC: Results From a Phase 1b Clinical Trial.

Autor: Garon EB; Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California. Electronic address: egaron@mednet.ucla.edu., Spira AI; Co-Director, Virginia Cancer Specialists Research Institute and NEXT Oncology, Fairfax, Virginia., Goldberg SB; Department of Internal Medicine, Yale Cancer Center, New Haven, Connecticut., Chaft JE; Department of Medicine, Weill Cornell Medical College and Memorial Sloan-Kettering Cancer Center, New York, New York., Papadimitrakopoulou V; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Cascone T; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Antonia SJ; H. Lee Moffitt Cancer Center, Tampa, Florida., Brahmer JR; Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland., Camidge DR; Department of Medicine-Medical Oncology, University of Colorado Cancer Center, Denver, Colorado., Powderly JD; Carolina BioOncology Institute, Huntersville, North Carolina., Wozniak AJ; Department of Medicine, University of Pittsburgh Hillman Cancer Center, Pittsburgh, Pennsylvania., Felip E; Deparmtent of Oncology, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain., Wu S; Oncology Research and Development, AstraZeneca, Gaithersburg, Maryland., Ascierto ML; Oncology Research and Development, AstraZeneca, Gaithersburg, Maryland., Elgeioushi N; Oncology Research and Development, AstraZeneca, Gaithersburg, Maryland., Awad MM; Dana-Farber Cancer Institute, Boston, Massachusetts.

Publikováno v: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2023 Aug; Vol. 18 (8), pp. 1094-1102. Date of Electronic Publication: 2023 May 04.

Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced ALK -Positive NSCLC.

Autor: Kim DW; Department of Internal Medicine, Seoul National University College of Medicine and Seoul National University Hospital, Seoul, South Korea., Gadgeel S; Department of Internal Medicine, Henry Ford Cancer Institute, Henry Ford Health System, Detroit, Michigan., Gettinger SN; Department of Medicine (Medical Oncology), Yale School of Medicine, New Haven, Connecticut., Riely GJ; Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Oxnard GR; Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., Mekhail T; AdventHealth Cancer Institute, Orlando, Florida., Schmid P; Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom., Dowlati A; Division of Hematology and Oncology, University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, Ohio., Heist RS; Massachusetts General Hospital Cancer Center, Boston, Massachusetts., Wozniak AJ; UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, Pennsylvania., Singh J; Genentech, Inc., South San Francisco, California., Cha E; Genentech, Inc., South San Francisco, California., Spahn J; Genentech, Inc., South San Francisco, California., Ou SI; University of California Irvine School of Medicine, Orange, California.

Publikováno v: JTO clinical and research reports [JTO Clin Res Rep] 2022 Jun 25; Vol. 3 (8), pp. 100367. Date of Electronic Publication: 2022 Jun 25 (Print Publication: 2022).

Characterization of KRAS Mutation Subtypes in Non-small Cell Lung Cancer.

Autor: Judd J; Department of Hematology-Oncology, Fox Chase Cancer Center, Temple University Health System, Philadelphia, Pennsylvania., Abdel Karim N; Department of Hematology-Oncology, Augusta University-Medical College of Georgia, Georgia Cancer Center, Augusta, Georgia., Khan H; Department of Hematology-Oncology, The Warren Alpert Medical School, Brown University, Providence, Rhode Isand., Naqash AR; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland.; Medical Oncology/TSET Phase 1 Program, Stephenson Cancer Center, University of Oklahoma, Oklahoma City, Oklahoma., Baca Y; Caris Life Sciences, Phoenix, Arizona., Xiu J; Caris Life Sciences, Phoenix, Arizona., VanderWalde AM; Department of Medical Oncology, West Cancer Center and Research Institute, Memphis, Tennessee., Mamdani H; Department of Oncology, Karmanos Cancer Institute/Wayne State University, Detroit, Michigan., Raez LE; Department of Hematology-Oncology, Memorial Cancer Institute/Memorial Health Care System/Florida International University, Hollywood, Florida., Nagasaka M; Department of Oncology, Karmanos Cancer Institute/Wayne State University, Detroit, Michigan., Pai SG; Department of Medical Oncology, Mitchell Cancer Institute, University of South Alabama, Mobile, Alabama., Socinski MA; Department of Medical Oncology, AdventHealth Cancer Institute, Orlando, Florida., Nieva JJ; Department of Medical Oncology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California., Kim C; Department of Hematology-Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC., Wozniak AJ; Department of Medical Oncology, University of Pittsburgh Medical Center, Hillman Cancer Center, University of Pittsburgh, Pittsburgh, Pennsylvania., Ikpeazu C; Department of Medical Oncology, Sylvester Comprehensive Cancer Center, University of Miami and the Miller School of Medicine, Miami, Florida., de Lima Lopes G Jr; Department of Medical Oncology, Sylvester Comprehensive Cancer Center, University of Miami and the Miller School of Medicine, Miami, Florida., Spira AI; Department of Medical Oncology, Virginia Cancer Specialists, US Oncology Research, Fairfax, Virginia., Korn WM; Caris Life Sciences, Phoenix, Arizona., Kim ES; Department of Medical Oncology, City of Hope, Los Angeles, California., Liu SV; Department of Hematology-Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC., Borghaei H; Department of Hematology-Oncology, Fox Chase Cancer Center, Temple University Health System, Philadelphia, Pennsylvania. hossein.borghaei@fccc.edu.

Publikováno v: Molecular cancer therapeutics [Mol Cancer Ther] 2021 Dec; Vol. 20 (12), pp. 2577-2584. Date of Electronic Publication: 2021 Sep 13.